Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy

Table 2

Relationship between demographic and clinical variables and the occurrence of HIV-sensory neuropathy.

Variables	SN present; 𝑁=126	SN absent; 𝑁=197	𝑃 value
Mean age ± SD, years	38.2±10.6	35.8±9.1	0.03
Male (𝑁=105)	48 (45.7%)	57 (54.3%)	0.09
Female (𝑁=218)	78 (35.8%)	140 (64.2%)
Mean height ± SD, metres	1.62±0.08	1.60±0.08	0.15
HAART treated (𝑁=142)	60 (42.3%)	82 (57.7%)	0.29
HAART naïve (𝑁=181)	66 (36.5%)	115 (63.5%)
Mean duration of HAART ± SD, months*	15.9±9.4	16.9±11.6	0.59
Stavudine-based HAART (𝑁=12)	10 (83.3%)	2 (16.7%)	0.003**
Non-stavudine-based HAART (𝑁=130)	50 (38.5%)	80 (61.5%)
Mean CD4 count ± SD, cells/mm^3	180.9±138.2	236.0±159.0	0.002
Median CD4 count ± SD, cells/mm^3	165.5	185.0
CD4 count ≤ 200, cells/mm^3 (𝑁=176)	74 (42.0%)	102 (58.0%)	0.22
CD4 count >200, cells/mm^3 (𝑁=147)	52 (35.4%)	95 (64.6%)

*Duration of therapy for the 142 participants on HAART therapy. **Fisher’s exact 𝑃 value.